J&J to sell its remaining 9.5% stake in Kenvue

Johnson & Johnson has said that it is planning to exit Kenvue, the consumer health business it spun out in 2022. The sale could be worth about $3.75bn, according to reports. J&J is focusing on its pharmaceutical and medical devises business.

Read the full article.